<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100506122334+02'00'</creation_date><modification_date>D:20100506122337+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_35.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission brussels, 5.5.2010 c(2010)3077</p></section><section><header>commission decision of 5.5.2010 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;pegintron - peginterferon alfa-2b&quot;, granted by decision c(2000)1407</header><p>(only the french and dutch texts are authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 5.5.2010 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;pegintron - peginterferon alfa-2b&quot;, granted by decision c(2000)1407 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, and in particular article 10(2) thereof, having regard to the application submitted by schering plough europe, on 26 october 
 2009, under article 14(2) of regulation (ec) no 726/2004 with a view to the renewal of 
 the marketing authorisation for the medicinal product &quot;pegintron - peginterferon alfa-2b&quot; 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 18 february 2010, 
 whereas: 
 (1)</p><p>on the basis of a re-evaluation by the agency of the risk-benefit balance 
 following the consideration of a consolidated file, it appears that the medicinal 
 product &quot;pegintron - peginterferon alfa-2b&quot;, entered in the community register of 
 medicinal products under number(s) eu/1/00/131/001-050 and authorised by 
 commission decision c(2000)1407 of 25 may 2000, complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 2. (2)</p><p>the marketing authorisation which expires on 5 june 2010 should therefore be 
 renewed. 
 (3)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>has adopted this decision: article 1 the marketing authorisation granted by decision c(2000)1407 of 25 may 2000 which expires on 5 june 2010 is renewed. 
 article 2 decision c(2000)1407 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 3 this decision is addressed to schering plough europe, rue de stalle, 73, 1180 bruxelles, belgique - stallestraat, 73 - 1180 brussel, belgiÃ«. 
 done at brussels, 5.5.2010.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>